Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  VIVUS, Inc.    VVUS

VIVUS, INC. (VVUS)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 12/15 09:59:46 pm
0.5326 USD   -3.16%
11/07 VIVUS : reports 3Q loss
11/07 VIVUS : Reports Third Quarter 2017 Financial Results
11/02 VIVUS : Completes Tacrolimus Pre-IND Meeting With FDA
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/11/2017 12/12/2017 12/13/2017 12/14/2017 12/15/2017 Date
0.578(c) 0.5599(c) 0.5801(c) 0.55(c) 0.5326(c) Last
805 435 634 913 1 197 564 725 547 679 188 Volume
-2.08% -3.13% +3.61% -5.19% -3.16% Change
More quotes
Financials ($)
Sales 2017 70,0 M
EBIT 2017 -
Net income 2017 -
Debt 2017 -
Yield 2017 -
Sales 2018 64,0 M
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0,81x
Capi. / Sales2018 0,88x
Capitalization 56,4 M
More Financials
Company
VIVUS, Inc. engages in the development and commercialization of novel therapeutic products.Its products include Qsymia and STENDRA/SPEDRA. The company was founded by Virgil A. Palace in April 16, 1991 and is headquartered in Mountain View, CA. 
Sector
Pharmaceuticals
Calendar
02/27Earnings Release
More about the company
Latest news on VIVUS, INC.
11/13 VIVUS INC : Results of Operations and Financial Condition, Financial Statements ..
11/07 VIVUS : reports 3Q loss
11/07 VIVUS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
11/07 VIVUS INC : Results of Operations and Financial Condition, Financial Statements ..
11/07 VIVUS : Reports Third Quarter 2017 Financial Results
11/07 VIVUS, INC. : to Host Earnings Call
11/02 VIVUS INC : Other Events, Financial Statements and Exhibits (form 8-K)
11/02 VIVUS : Completes Tacrolimus Pre-IND Meeting With FDA
10/31 VIVUS INC : Change in Directors or Principal Officers, Submission of Matters to ..
10/31 VIVUS : to Host Third Quarter Business Update and Financial Results Conference C..
More news
Sector news : Biopharmaceuticals
02:06p TEVA PHARMACEUTICAL INDUSTRIES : Strike briefly shuts down Israel over Teva Phar..
12/16 NELSON PELTZ : P&G appoints Peltz to board despite losing proxy battle
12/16 PROCTER & GAMBLE : P&G appoints Peltz to board despite losing proxy battle
12/15 JAZZ PHARMACEUTICALS : Pennsylvania man admits to trading on tips about drug com..
12/15DJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
More sector news : Biopharmaceuticals
4-Traders Strategies on VIVUS, INC. 
VIVUS - 2013
Bearish trend should continue
SELL
More Strategies
News from SeekingAlpha
11/07 Vivus' (VVUS) CEO Seth Fischer on Q3 2017 Results - Earnings Call Transcript
11/07 Vivus beats by $0.07, misses on revenue
11/06 Notable earnings after Tuesday?s close
10/05 YOUR DAILY PHARMA SCOOP : The First Trust NYSE Arca Biotechnology Index, Gilead'..
09/06 VIVUS' tacrolimus an Orphan Drug in Europe for pulmonary arterial hypertensio..
Chart VIVUS, INC.
Duration : Period :
VIVUS, Inc. Technical Analysis Chart | VVUS | US9285511005 | 4-Traders
Technical analysis trends VIVUS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 1,50 $
Spread / Average Target 182%
EPS Revisions
Managers
NameTitle
Seth H. Z. Fischer Chief Executive Officer & Director
David York Norton Chairman
Mark K. Oki Chief Financial & Accounting Officer
Santosh T. Varghese Chief Medical Officer
Jorge Plutzky Director
Sector and Competitors
1st jan.Capitalization (M$)
VIVUS, INC.-49.56%56
BIOGEN23.81%69 352
CSL LIMITED40.24%48 543
ALEXION PHARMACEUTICALS-7.57%25 862
GRIFOLS SA28.81%17 812
BIOMARIN PHARMACEUTICAL7.03%16 336